These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9071267)

  • 21. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.
    Seaber E; On N; Phillips S; Churchus R; Posner J; Rolan P
    Br J Clin Pharmacol; 1996 Feb; 41(2):141-7. PubMed ID: 8838441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
    Tuchman M; Hee A; Emeribe U; Silberstein S
    CNS Drugs; 2006; 20(12):1019-26. PubMed ID: 17140280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zolmitriptan provides consistent migraine relief when used in the long-term.
    Tuchman M; Edvinsson L; Geraud G; Korczyn A; Mauskop A; Pfaffenrath V
    Curr Med Res Opin; 1999; 15(4):272-81. PubMed ID: 10640259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of zolmitriptan and its clinical applications in migraine.
    Dowson AJ; Charlesworth B
    Expert Opin Pharmacother; 2002 Jul; 3(7):993-1005. PubMed ID: 12083998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
    Martin GR
    Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
    Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
    Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
    Rolan P
    Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.
    Gallagher RM; Dennish G; Spierings EL; Chitra R
    Headache; 2000 Feb; 40(2):119-28. PubMed ID: 10759911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
    Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
    Dowson AJ; Charlesworth BR; Green J; Färkkilä M; Diener HC; Hansen SB; Gawel M;
    Headache; 2005 Jan; 45(1):17-24. PubMed ID: 15663608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical efficacy of zolmitriptan in migraine].
    Leira R; Noya M
    Neurologia; 1998 Oct; 13 Suppl 2():16-24. PubMed ID: 9859691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
    Deleu D; Hanssens Y
    Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spotlight on almotriptan in migraine.
    Keam SJ; Goa KL; Figgitt DP
    CNS Drugs; 2002; 16(7):501-7. PubMed ID: 12056924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Almotriptan: a review of its use in migraine.
    Keam SJ; Goa KL; Figgitt DP
    Drugs; 2002; 62(2):387-414. PubMed ID: 11817980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging preclinical and clinical profile of 311C90: a poster review and discussion.
    Ferrari MD
    Eur Neurol; 1996; 36 Suppl 2():19-23. PubMed ID: 8791028
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
    Geraud G; Olesen J; Pfaffenrath V; Tfelt-Hansen P; Zupping R; Diener HC; Sweet R
    Cephalalgia; 2000 Feb; 20(1):30-8. PubMed ID: 10817444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
    Proietti-Cecchini A; Afra J; Schoenen J
    Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study.
    Loder E; Silberstein SD; Abu-Shakra S; Mueller L; Smith T
    Headache; 2004 Feb; 44(2):120-30. PubMed ID: 14756849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study.
    Geraud G; Compagnon A; Rossi A;
    Eur Neurol; 2002; 47(2):88-98. PubMed ID: 11844897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.